首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   306262篇
  免费   71516篇
  国内免费   8260篇
耳鼻咽喉   6805篇
儿科学   9946篇
妇产科学   3551篇
基础医学   27520篇
口腔科学   7749篇
临床医学   46823篇
内科学   77771篇
皮肤病学   14921篇
神经病学   29072篇
特种医学   11938篇
外国民族医学   22篇
外科学   63426篇
综合类   17881篇
现状与发展   90篇
一般理论   26篇
预防医学   17248篇
眼科学   6188篇
药学   15532篇
  70篇
中国医学   6263篇
肿瘤学   23196篇
  2024年   898篇
  2023年   5703篇
  2022年   3701篇
  2021年   7731篇
  2020年   13594篇
  2019年   14864篇
  2018年   17875篇
  2017年   19170篇
  2016年   20629篇
  2015年   21937篇
  2014年   29927篇
  2013年   30797篇
  2012年   16235篇
  2011年   16521篇
  2010年   23522篇
  2009年   23228篇
  2008年   13142篇
  2007年   10356篇
  2006年   12567篇
  2005年   9077篇
  2004年   7197篇
  2003年   6286篇
  2002年   6058篇
  2001年   7082篇
  2000年   5561篇
  1999年   4839篇
  1998年   4495篇
  1997年   4322篇
  1996年   3998篇
  1995年   3770篇
  1994年   2385篇
  1993年   1863篇
  1992年   1787篇
  1991年   1763篇
  1990年   1358篇
  1989年   1470篇
  1988年   1258篇
  1987年   1067篇
  1986年   1064篇
  1985年   897篇
  1984年   613篇
  1983年   593篇
  1982年   551篇
  1981年   440篇
  1980年   376篇
  1979年   341篇
  1978年   352篇
  1977年   412篇
  1975年   293篇
  1972年   322篇
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
3.
4.
5.

Background

In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).

Methods

This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.

Results

The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.

Conclusions

These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.

Plain Language Summary

  • Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
  • Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
  • Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
  • Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
  相似文献   
6.
ABSTRACT

Abortion is legal in South Africa, but negative abortion attitudes remain common and are poorly understood. We used nationally representative South African Social Attitudes Survey data to analyze abortion attitudes in the case of fetal anomaly and in the case of poverty from 2007 to 2016 (n = 20,711; ages = 16+). We measured correlations between abortion attitudes and these important predictors: religiosity, attitudes about premarital sex, attitudes about preferential hiring and promotion of women, and attitudes toward family gender roles. Abortion acceptability for poverty increased over time (b = 0.05, p < .001), but not for fetal anomaly (b = ?0.008, p = .284). Highly religious South Africans reported lower abortion acceptability in both cases (Odds Ratio (OR)anomaly = 0.85, p = .015; ORpoverty = 0.84, p = .02). Premarital sex acceptability strongly and positively predicted abortion acceptability (ORanomaly = 2.63, p < .001; ORpoverty = 2.46, p < .001). Attitudes about preferential hiring and promotion of women were not associated with abortion attitudes, but favorable attitudes about working mothers were positively associated with abortion acceptability for fetal anomaly ((ORanomaly = 1.09, p = .01; ORpoverty = 1.02, p = .641)). Results suggest negative abortion attitudes remain common in South Africa and are closely tied to religiosity, traditional ideologies about sexuality, and gender role expectations about motherhood.  相似文献   
7.
Abstract

Background

Comorbidities are commonly seen in patients with coronavirus disease 2019 (COVID-19), but the clinical implication is not yet well-delineated. We aim to characterize the prevalence and clinical implications of comorbidities in patients with COVID-19.  相似文献   
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号